Sign inJoin waitlistJoin the waitlist

Matthew Lunning

Assistant Vice Chancellor for Clinical Research · University of Nebraska Medical Center College of Medicine

Credentials: · · · · · ·

History

Department of Internal Medicine · University of Nebraska Medical Center College of Medicine
Present
UNMC Division of Hematology · University of Nebraska Medical Center College of Medicine
Present
University of Nebraska Medical Center College of Medicine
Present

Memorial Sloan Kettering Cancer Center
2013–2015
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2010–2013
Internal Medicine
University of Nebraska Medical Center College of Medicine
2006–2009
Des Moines University College of Osteopathic Medicine
2002–2006
Gustavus Adolphus College
2002

Research

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · 2,058 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or…
The Lancet · 2022 · 698 citations
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 2020 · 691 citations

Julie Vose
31 papers
SH
Steven Horwitz
23 papers
JA
Jeremy Abramson
19 papers
Manali Kamdar
18 papers
James Armitage
17 papers
Veronika Bachanova
12 papers
AM
Alison Moskowitz
11 papers
Brian Hill
11 papers
FL
Frederick Locke
11 papers
Jon Arnason
10 papers
Robert Bociek
10 papers
SS
Scott Solomon
10 papers

Clinical trials

Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Principal investigator · Withdrawn
University of Nebraska
2021
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Principal investigator · Completed · Phase 2
University of Nebraska
2016–2019
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
University of Nebraska
2015–2020
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032